Nat. Rev. Urol. doi: /nrurol

Slides:

Advertisements

Similar presentations

Bladder Cancer Ishan Parikh. Where and What? The bladder… -stores urine received from the kidneys -is about the size of a pear when empty -is a very elastic.

Advertisements

EORTC scores of recurrence and progression in a Romanian cohort First author: Anda Ştefan Co-authors: Radu Mihail Boja, PhD Ovidiu Ioan Golea, PhD Ladislau.

Contemporary Treatment Guidelines on Bladder Cancer

Efficacy of sodium hyaluronate in the management of chemical and radiation cystitis Sommariva et al. Minerrva Urol Nefrol 2010.

Trends in bladder cancer treatments

Nat. Rev. Urol. doi: /nrurol

Figure 1 Number of somatic mutation rates across The Cancer Genome Atlas (TCGA) projects Figure 1 | Number of somatic mutation rates across The Cancer.

Nat. Rev. Urol. doi: /nrurol

Figure 4 Types of urinary diversion

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recruitment of experts to the Delphi study

Volume 61, Issue 1, Pages (January 2012)

Nat. Rev. Urol. doi: /nrurol

Mr Niall Gilliland Miss Helena Burden Miss Kate Warren

Figure 1 The UMBRELLA SIOP-RTSG 2016 protocol logo

Figure 5 Types of urinary diversion

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Cellular processes involved in cancer development

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Urol. doi: /nrurol

Figure 3 Semantic model of the active surveillance (AS) timeline

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Urol. doi: /nrurol

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Key elements of the proposed modified Delphi study

Nat. Rev. Urol. doi: /nrurol

Figure 6 Common signalling mechanisms, pathways,

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 1 The development process of the Asian

Figure 1 Differences in bladder cancer between genders

Figure 13 Proposed management of bladder cancer with variant histology

Nat. Rev. Urol. doi: /nrurol

Figure 3 Treatment algorithm for adult infertile men with varicoceles

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

chemotherapy for patients with MC versus those with AC

Nat. Rev. Urol. doi: /nrurol

Figure 2 Temporal summation

Figure 1 Decision tree integrating the assessment,

Figure 6 Image sequence demonstrating coronal cuts on MRI

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Figure 3 Template for standard pelvic lymphadenectomy

Nat. Rev. Urol. doi: /nrurol

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Urinary bladder cancer

Nat. Rev. Urol. doi: /nrurol

Figure 4 The grey zone between active

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Urol. doi: /nrurol

Figure 2 Recommended simulation training pathway

Figure 3 Target volume definitions

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Determination of the primary site

Figure 4 Algorithm for when to determine PTEN

Volume 54, Issue 1, Pages (July 2008)

E2F4 program is predictive of the efficacy of intravesical BCG immunotherapy in NMIBC. A, the survival curves of intravesical therapy-treated and untreated.

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Nat. Rev. Urol. doi:10.1038/nrurol.2017.16 Figure 1 Classification of patients with high-risk NMIBC after intravesical BCG and types of BCG failure Figure 1 | Classification of patients with high-risk NMIBC after intravesical BCG and types of BCG failure. Distinct categories of clinical responses to BCG are determined by treatment duration/sequence, clinical response, and timing of clinical response, which are represented in the flowchart. CIS, carcinoma in situ; NMIBC, non-muscle-invasive bladder cancer; TUR, transurethral resection. Kamat, A. M. et al. (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG Nat. Rev. Urol. doi:10.1038/nrurol.2017.16